Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Elena Elez Fernandez"'
Autor:
Davide Ciardiello, Giulia Martini, Vincenzo Famiglietti, Stefania Napolitano, Vincenzo De Falco, Teresa Troiani, Tiziana Pia Latiano, Javier Ros, Elena Elez Fernandez, Pietro Paolo Vitiello, Evaristo Maiello, Fortunato Ciardiello, Erika Martinelli
Publikováno v:
Cancers, Vol 14, Iss 16, p 3900 (2022)
In the original publication [...]
Externí odkaz:
https://doaj.org/article/6f70790307e546d9a077022735f44a11
Autor:
Davide Ciardiello, Giulia Martini, Vincenzo Famiglietti, Stefania Napolitano, Vincenzo De Falco, Teresa Troiani, Tiziana Pia Latiano, Javier Ros, Elena Elez Fernandez, Pietro Paolo Vitiello, Evaristo Maiello, Fortunato Ciardiello, Erika Martinelli
Publikováno v:
Cancers, Vol 13, Iss 8, p 1941 (2021)
The prognosis of patients with metastatic colorectal cancer (mCRC) who progressed to the first and the second lines of treatment is poor. Thus, new therapeutic strategies are needed. During the last years, emerging evidence suggests that retreatment
Externí odkaz:
https://doaj.org/article/ea7ff3e218ce4df38bbe2a4fdd5fe875
Autor:
Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja J. A. de Jonge, Jean-Yves Blay, Antoine Italiano, Kan Yonemori, Daniel C. Cho, Filip Y. F. L. de Vos, Philippe Moreau, Elena Elez Fernandez, Jan H. M. Schellens, Christoph C. Zielinski, Suman Redhu, Aislyn Boran, Vanessa Q. Passos, Palanichamy Ilankumaran, Yung-Jue Bang
Publikováno v:
Nature medicine, vol 29, iss 5
Scientia
Nature Medicine, 29(5), 1103-1112. Nature Publishing Group
Scientia
Nature Medicine, 29(5), 1103-1112. Nature Publishing Group
BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor) in eight cohorts of patients with BRAFV600E-
Autor:
Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja JA Jonge, Jean-Yves Blay, Antoine Italiano, Kan Yonemori, Daniel C. Cho, Filip YFL de Vos, Philippe Moreau, Elena Elez Fernandez, Jan H. Schellens, Christoph C. Zielinski, Suman Redhu, Vanessa Q. Passos, Palanichamy Ilankumaran, Yung-Jue Bang
Publikováno v:
Cancer Research. 83:CT083-CT083
Beyond melanoma, BRAFV600E alterations are prevalent across multiple tumors. We conducted a basket trial (NCT02034110) to assess efficacy and safety of oral BRAF inhibitor dabrafenib (150 mg BD) plus MEK inhibitor trametinib (2 mg OD) in 206 patients
Autor:
Elena López-Miranda, Eva Guerra, Jose L Casado, Maria Gion, Hector Velasco, Noelia Martínez-Jañez, Diana Rosero, Maria Elena Elez Fernandez, Juan José Serrano, Cristina Saavedra, Jesús Chamorro, Alfredo Carrato, Alejandro Vallejo, Alfonso Cortes, Federico Longo, Adrian Martin
SARS-CoV-2 vaccination in cancer patients has become crucial because of their higher risk of complications and death from COVID19. We performed a prospective study to assess the immunogenicity of SARS-CoV-2 vaccine in cancer patients treated with CDK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3840fc2614e76af50c71343a03107670
https://doi.org/10.21203/rs.3.rs-798329/v1
https://doi.org/10.21203/rs.3.rs-798329/v1
Autor:
Antonio Cubillo Gracian, Marina Nechaeva, Ramesh K. Ramanathan, Danielle Sullivan, Jordan Berlin, Elena Elez Fernandez, Ralf Hofheinz, Vera Gorbunova, Dustin A. Deming, Alison Torres, J. Thaddeus Beck, Yan Luo, László Mangel, P. García-Alfonso
Publikováno v:
British Journal of Cancer
Background Metastatic colorectal cancer (mCRC) has low survival rates. We assessed if addition of veliparib, concurrent to FOLFIRI, improves survival in patients with previously untreated mCRC. Methods This study compared veliparib (200 mg BID for 7
Autor:
Stefania Napolitano, Vincenzo Famiglietti, Vincenzo De Falco, J. Ros, Elena Elez Fernandez, Pietro Paolo Vitiello, Fortunato Ciardiello, Evaristo Maiello, Tiziana Latiano, Teresa Troiani, Giulia Martini, Davide Ciardiello, Erika Martinelli
Publikováno v:
Scientia
Cancers
Cancers, Vol 13, Iss 1941, p 1941 (2021)
Cancers
Cancers, Vol 13, Iss 1941, p 1941 (2021)
Simple Summary The survival of patients with metastatic colorectal cancer (mCRC) has been improved over the years and now reaches 30–40 months. However, few therapeutic options are available after failure of first- and second-line treatments. In fa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1d23bbe392ea27e821274084d713013
https://hdl.handle.net/11351/6741
https://hdl.handle.net/11351/6741
Autor:
J. Thaddeus Beck, Antonio Cubillo Gracian, Yan Luo, P. García-Alfonso, Ramesh K. Ramanathan, Ralf Hofheinz, László Mangel, Danielle Sullivan, Elena Elez Fernandez, Alison Torres, Jordan Berlin, Vera Gorbunova, Marina Nechaeva, Dustin A. Deming
Publikováno v:
British Journal of Cancer. 121:429-430
The original version of this article contained an error in Figure 1a. The number of patients at risk listed in the Veliparib arm of Figure 1a should have read “65” instead of “35”. An amendment to this paper has been published and can be acce
Autor:
Jason E. Faris, Eli L. Diamond, Martina Makrutzki, Vivek Subbiah, Antoine Hollebecque, Maria Luisa Veronese, Maria Elena Elez-Fernandez, David M. Hyman, Radj Gervais, Juergen Wolf, Josep Tabernero, Igor Puzanov, Susan Frances Lasserre, Noopur Raje, Martin Schuler, Jean-Yves Blay, José Baselga, Emily Chan, Ian Chau, Ralf-Dieter Hofheinz, Florin Sirzen, Manuel Hidalgo, Antoine Italiano
BackgroundBRAF V600 mutations occur in various nonmelanoma cancers. We undertook a histology-independent phase 2 “basket” study of vemurafenib in BRAF V600 mutation–positive nonmelanoma cancers. MethodsWe enrolled patients in six prespecified c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db07b26d091caa624e875997ead64da8
http://europepmc.org/articles/pmc4971773
http://europepmc.org/articles/pmc4971773
Autor:
Maria Elena Elez Fernandez, Jonathan D. Cheng, Dong Wan Kim, Bilal Piperdi, Janice M. Mehnert, Rebecca A. Moss, Sandrine Hiret, Patrick A. Ott, Tammy Winser, Sammy Yuan
Publikováno v:
Journal of Clinical Oncology. 33:7502-7502
7502 Background: Treatment options for pts with SCLC that progresses on platinum-based chemotherapy are limited. Pembrolizumab, an anti–PD-1 monoclonal antibody designed to block the interaction be...